Sometimes I forget, and I think we all forget, the big picture around what we are actually doing.
Drug development is so intense that it can shrink your world down to the next assay, the next dataset, the next meeting, and the next “why did this fail?” moment. But I want to zoom out for a minute because the mission is brutal and simple. We take a messy, uncertain universe of biology, patients, risk, regulation, manufacturing, and markets, and we compress it into one thing that works. We make a real thing. We make a safe thing. We make a thing doctors will prescribe, payers will cover, and patients will stay on.
I often think about sculpture when I think about this work. A sculptor does not start by adding detail. A sculptor starts by removing what does not belong. A team starts with a big ugly block and chips away until what is left is the “shiny marble.”
That is the big picture. It is also why the “next successful drug” is not only about efficacy. It is about the full stack.
Here are the elements I think about when I ask, “Could this become a real winner?”
First, I look for the clinical truth. I ask whether the drug helps patients in a meaningful way. I do not mean a statistically interesting way. I mean a meaningful way. I look for better outcomes, fewer side effects, better adherence, and better quality of life. This is where the science earns the right to exist.
Second, I look at safety and tolerability. I know the most effective compound in the world is useless if it cannot survive safety scrutiny, or if patients will not stay on it. Safety is not a box to check. Safety is the boundary of the entire business.
Third, I look at developability. I ask whether the molecule can be formulated, delivered, stored, and scaled. I ask whether it is stable. I ask whether it has a reasonable PK/PD profile. I ask whether it behaves like something that can live in a supply chain and a clinic.
Fourth, I look at manufacturability. I ask whether a team can make it at scale, consistently, with quality, without bankrupting the program. This is where many beautiful ideas die quietly.
Fifth, I look at regulatory and evidence strategy. I ask what endpoints matter. I ask what trials are feasible. I ask what comparators will be required. I ask what evidence will convince regulators, and what evidence will convince payers and guidelines committees later.
Sixth, I look at IP and patentability. I do not only ask whether someone can get a patent. I ask whether the space is defensible enough to justify the investment curve. I also recognize that the closer a program gets to a blockbuster category, the more crowded and adversarial the landscape becomes.
Seventh, I look at commercial reality. I ask who the patient is. I ask who the prescriber is. I ask what creates adoption friction. I ask what changes behavior. I ask what the payer story is. This part can feel uncomfortable, but it is true. A great drug can still fail if the market path is wrong.
Eighth, I look for differentiation. I ask why this drug should win now versus what already exists. I also ask what will exist by the time the drug launches. Time is the silent competitor in every program.
This is where “white space” matters.
In plain terms, white space is the gap between what patients need and what the market currently serves well. White space can be a new mechanism. White space can be a better safety profile. White space can be a simpler delivery method. White space can be a way to treat a population that nobody is addressing properly. Sometimes white space is a new indication hiding inside an old category.
Ozempic is a good example of a “white whale” that became a new gravitational center. GLP-1 science existed. Metabolic disease existed. But the combination of clinical results, patient impact, and commercial flywheel created a category shift. Keytruda is another example in immuno-oncology. It did not succeed because someone discovered cancer. It succeeded because a usable clinical strategy met the moment and because the evidence base supported broad adoption.
So how does a person research their way toward the next one?
A person does not start with the molecule. A person starts with the constraints.
A team starts with the patient and the unmet need. A team maps the current standard of care. A team identifies what fails and why it fails. Then the team widens the lens and pressure-tests every layer: mechanism options, delivery options, adherence realities, payer realities, manufacturing realities, regulatory realities, and IP realities. This approach is not a hunt for a magic bullet. This approach is a disciplined process of carving away dead ends.
That is the work. A team builds a funnel that gets narrower and narrower until what remains is not merely “interesting.” What remains is viable.
The shiny marble is not only a compound. The shiny marble is a compound that can survive the whole world.